Gut Bacteria Shape Therapeutic Response.
The composition of patients' gut microbiomes influences whether they will respond to anti-PD-1 therapy, according to a trio of recently published studies. One of the studies also found that using antibiotics can reduce treatment efficacy, presumably by killing important species of gut bacteria. Now researchers are investigating how these findings can be used to increase the proportion of patients who respond to checkpoint inhibitor therapy.